FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
New schizophrenia drug ‘could change the lives of millions of people’
The US Food and Drug Administration has approved Cobenfy, which is owned by pharmaceutical firm Bristol Myers Squibb.
First novel Schizophrenia treatment in decades gains FDA approval
The first new kind of treatment for schizophrenia patients in decades is arriving. The U.S. Food and Drug Administration ...
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, Wynn, HP Inc., Acadia Healthcare, and More
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
btimesonline51m
FDA Approves Bristol Myers Squibb’s Cobenfy, First Novel Schizophrenia Drug in 70 Years
Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...
Top Stock Movers Now: Wynn Resorts, AT&T, Newmont, and More
U.S. equities were mixed at midday as the Federal Reserve's favored measure of inflation was lower than anticipated.
Dow advances to record high after inflation report; small caps outperform
The blue-chip Dow rose on Friday to hit an intraday record and small-cap stocks outperformed after a benign inflation report ...
WH National Security spokesman on plans for Israel-Hezbollah truce
ABC News' Linsey Davis speaks with White House National Security spokesman John Kirby on the latest in the cease-fire negotiations between Lebanon and Israel as tensions escalate in the region.
BioPharma Dive12m
J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers
Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain. Dermavant’s sale to Organon ...